Publications

STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

Download PDF
Resource: STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

.

Related Articles

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

Link

Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential

Link